DEF: Champions Oncology Sets Oct. 14 Annual Meeting, Seeks Equity Plan Approval

Champions Oncology, Inc. has announced its Annual Meeting of Stockholders scheduled for October 14, 2026, with key proposals including the election of directors and the approval of the 2026 Equity Incentive Plan.

Summary

• Champions Oncology, Inc. is holding its Annual Meeting of Stockholders on October 14, 2026, at its Hackensack, New Jersey headquarters.
• The meeting agenda includes the election of seven directors, ratification of EisnerAmper LLP as the independent auditor for fiscal year 2027, and advisory votes on executive compensation and its frequency.
• A significant proposal is the approval of the 2026 Equity Incentive Plan, designed to attract and retain talent by offering equity awards.
• The Record Date for determining stockholders entitled to vote is August 21, 2026, with 13,918,571 shares of common stock outstanding.
• Proxy materials will be made available online, with a notice mailed to stockholders around August 31, 2026.
• The Board of Directors recommends voting 'FOR' all proposals, including the director nominees, auditor ratification, executive compensation, frequency of compensation votes, and the new equity incentive plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, primarily due to the proactive approach in seeking shareholder approval for a new equity incentive plan and the clear, structured presentation of annual meeting matters. The company is maintaining good corporate governance practices.

Positives

• Proactive scheduling of the Annual Meeting of Stockholders for October 14, 2026.
• Clear agenda items presented for stockholder vote, including director elections and auditor ratification.
• Proposal of a new 2026 Equity Incentive Plan aimed at attracting and retaining key personnel.
• Commitment to good corporate governance through advisory votes on executive compensation and its frequency.
• EisnerAmper LLP, the current auditor, is proposed for reappointment, indicating a stable auditor relationship.
• The company is utilizing e-proxy to reduce costs and improve accessibility of proxy materials.

Negatives

• The filing does not contain financial performance results, as it is a proxy statement for an upcoming meeting.
• The company's net loss of $1,175,000 in fiscal year 2026, as indicated in the Pay vs. Performance table, suggests ongoing financial challenges.

Risks

• Failure to approve the 2026 Equity Incentive Plan could adversely affect the company's ability to recruit, retain, and incentivize top talent.
• If stockholders do not ratify the appointment of EisnerAmper LLP, the Audit Committee will reconsider the firm, potentially leading to a change in auditors.
• The advisory vote on executive compensation, while non-binding, could signal stockholder dissatisfaction if a significant number vote against it, impacting management morale and future compensation decisions.
• The company's reliance on equity awards for compensation, as detailed in the 2026 Equity Incentive Plan, carries inherent market risks and dilution concerns for existing shareholders.

Future Outlook

The primary forward-looking aspect is the proposed 2026 Equity Incentive Plan, which aims to incentivize employees, consultants, and directors to promote long-term success and shareholder value by granting equity awards. The company anticipates that this plan will be crucial for attracting and retaining qualified talent.

Management Comments

• "The Board of Directors recommends that stockholders vote FOR all of the proposed nominees for director, FOR the ratification of the appointment of EisnerAmper LLP, FOR the approval of the advisory vote on the frequency of holding stockholder advisory votes on executive compensation, and FOR the non-binding resolution approving the compensation of our named executive officers, FOR the non-binding advisory vote on the frequency of holding stockholder advisory votes on executive compensation, and FOR the approval of the Incentive Plan."
• "Unless you provide specific instructions as to how to vote, brokers may not vote your shares of common stock on the election of directors or the non-binding advisory resolutions relating to the compensation of our named executive officers."
• "The Board of Directors has unanimously recommends that the stockholders vote 'FOR' the approval of the 2026 Equity Incentive Plan."

Industry Context

StockSavvy.ai notes that the proposal of an equity incentive plan is a common and often necessary strategy in the biotechnology and healthcare sectors, where attracting and retaining specialized talent is critical. The focus on aligning executive and director interests with shareholder value through stock ownership is a standard practice aimed at driving long-term growth.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. David Sidransky, a director who beneficially owned approximately 6.0% of the common stock as of the Record Date, received $0 in consulting fees during the fiscal year ended April 30, 2026, and $12,000 during the fiscal year ended April 30, 2025.

Stakeholder Impact

• Shareholders: Voting rights on key corporate matters, potential dilution from the new equity incentive plan, and advisory input on executive compensation.
• Employees: Eligibility for equity awards under the proposed 2026 Equity Incentive Plan, aimed at motivation and retention.
• Directors: Election to the Board, compensation for their services, and potential equity awards.
• Auditors (EisnerAmper LLP): Proposed reappointment for fiscal year 2027, subject to stockholder ratification.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on October 14, 2026.
• The Board of Directors will review the outcome of the advisory votes on executive compensation and its frequency.
• If approved, the 2026 Equity Incentive Plan will become effective, allowing the company to grant equity awards.
• Preliminary voting results will be announced at the meeting, with final results filed on Form 8-K within four business days.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data or significant strategic shifts that would warrant a buy or sell recommendation. The proposals are standard for corporate governance and compensation. While the equity plan is positive for talent management, the company's recent net loss in FY2026 suggests caution. Therefore, a 'hold' recommendation is appropriate pending further financial performance updates.

Keywords

Annual Meeting, Proxy Statement, Equity Incentive Plan, Director Election, Executive Compensation, Auditor Ratification, Stockholder Vote, Corporate Governance